EndothelinA–EndothelinB Receptor Cross Talk in Endothelin-1–Induced Contraction of Smooth Muscle
RM Rapoport, M Zuccarello - Journal of cardiovascular …, 2012 - journals.lww.com
RM Rapoport, M Zuccarello
Journal of cardiovascular pharmacology, 2012•journals.lww.comThe efficacy of selective endothelin (ET) receptor antagonists may be limited by a functional
interaction between the ET A and ET B receptors. This interaction, also termed “cross talk”, is
characterized by the dependency of the inhibition of an ET-1 response due to antagonism of
one ET receptor subtype upon concomitant antagonism of the other ET receptor subtype.
Although a reduction in ET A-ET B receptor cross talk would presumably increase the
efficacy of selective ET receptor antagonists, an approach that accomplishes this aim is …
interaction between the ET A and ET B receptors. This interaction, also termed “cross talk”, is
characterized by the dependency of the inhibition of an ET-1 response due to antagonism of
one ET receptor subtype upon concomitant antagonism of the other ET receptor subtype.
Although a reduction in ET A-ET B receptor cross talk would presumably increase the
efficacy of selective ET receptor antagonists, an approach that accomplishes this aim is …
Abstract
The efficacy of selective endothelin (ET) receptor antagonists may be limited by a functional interaction between the ET A and ET B receptors. This interaction, also termed “cross talk”, is characterized by the dependency of the inhibition of an ET-1 response due to antagonism of one ET receptor subtype upon concomitant antagonism of the other ET receptor subtype. Although a reduction in ET A-ET B receptor cross talk would presumably increase the efficacy of selective ET receptor antagonists, an approach that accomplishes this aim is largely absent due to a lack of mechanistic understanding. Toward this goal, we evaluated the characteristics and potential dependencies of cross talk in smooth muscle. Smooth muscle was adopted as an exemplar not only because cross talk is widely reported in this tissue type, thereby allowing numerous comparisons, but also significant controversy surrounds the use of selective versus nonselective ET receptor antagonists in ET-1–related pathophysiologies involving smooth muscle. Based on this evaluation, we suggest that ET A-ET B receptor cross talk is a dynamic process directed by either or both ET receptor subtypes and expressed to varying magnitudes depending on the ET-1 and selective ET receptor antagonist concentrations, tone due to intraluminal pressure/stretch, agonists acting at receptors other than the ET A/ET B receptors, and endothelial/epithelial function. It is speculated that ET A-ET B receptor cross talk occurs through signal transduction pathways along with changes at the receptor level. Pharmacologic intervention of the signaling pathways could increase the therapeutic efficacy of ET receptor antagonists.
Lippincott Williams & Wilkins
以上显示的是最相近的搜索结果。 查看全部搜索结果